
# Hepatitis B prevention in the Republic of Korea

Jong-Hyun Kim / Yae-Jean Kim Department of Paediatrics, College of Medicine The Catholic University of Korea / Sungkyunkwan University

### Hepatitis B prevalence/incidence

	HBsAg positives
General population (≥10 yrs) [2014]	2.9% (M 3.2%, F 2.7%)
Pre-school ages (4-6 yrs) [2006]	0.2%
School ages (10-18 yrs) [2014]	0.1%
Pregnant women [2011]	1.4%, 19-29 yrs 3.5%, 30-39 yrs
	HBeAg positives
HBsAg positive pregnant women [2010]	35.2%

#### Changes of HBsAg positive rate in Korea





### Vaccination schedules 2018



Available free from the gov. Recommended not for free

#### Immunization schedule

Disease	Vaccine Name/brand	Birth	≤4w	1m	2m	4m	6m	12m	15m	18m	19- 23m	24- 35m	4Y	6Y	11Y	12Y
НерВ	Hepavax, Euvax	1st		2nd			3rd									
BCG	Danish (ID), Tokyo (PC)		1st													
DTaP	DTaP, DTaP-IPV, DTaP-IPV-Hib				1st	2nd	3rd		41	4th			5	th	Тс	lap
Polio	IPV				1st	2nd	3rd						4	th		
PCV, Hib	PCV13 or PCV10 / Hib (LG)				1st	2nd	3rd	41	th							
Rotavirus	Rotateq, Rotarix				1st	2nd	3rd									
MMR								1:	st	t			2	nd		
VZ								1st								
Flu								yearly								
НерА								1st AND 2nd								
JE	Cell culture							1st AND 2nd			3rd		4th		5th	
JE (live)	Chundu, SanofiPasteur							1st			2nd					
HPV	HPV2, HPV4 or HPV9												1st AN	ND 2nd		



Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

### Vaccination coverage rate

Vaccines	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
BCG	97	98	99	99	99	99	96	96	96	96	98	97	93	87	89	81	73	74	75	91	92
DTP1	98	99	99	99	99	99	96	96	95	95	98	98	95	97	97	97	97	96	94	93	96
DTP3	98	98	99	99	99	99	94	94	94	91	98	96	88	97	97	97	97	86	74	80	90
HepB3	98	98	99	99	99	99	94	94	94	91	99	99	92	91	92	89	93	88	82	88	93
HepB_BD	93	93	92	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Hib3	98	98	97	_	-	-	-	-	-	-	-	-	-	-	_	-	-	-	-	_	_
MCV1	98	98	99	99	99	99	98	93	92	92	99	99	99	96	97	96	95	90	85	85	89
MCV2	97	97	96	95	97	98	98	99	99	99	99	99	99	95	95	67	39	_	_	_	_
PCV3	98	97	-	_	-	-	-	-	-	_	-	-	_	-	_	-	-	-	-	-	_
Pol3	98	98	99	99	99	98	95	95	92	91	98	96	90	94	99	99	99	85	71	81	91
RCV1	98	98	99	99	99	99	98	93	92	92	99	99	99	96	97	96	95	90	85	85	89
RotaC	_	_	-	_	-	-	_	-	-	_	-	-	_	-	_	_	_	_	_	_	_

Vaccines	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1980
BCG	93	93	88	83	77	72	70	57	54	47	47	47	45	44	42
DTP1	99	97	96	94	92	90	96	80	80	91	91	91	87	82	82
DTP3	99	93	88	84	79	74	89	58	57	76	76	76	69	61	61
HepB3	99	_	_	-	_	_	-	_	_	-	_	_	_	_	-
HepB_BD	-	-	-	-	-	_	-	-	-	-	-	-	_	_	-
Hib3	_	_	_	_	_	_	_	_	_	_	_	_	_	_	-
MCV1	93	92	92	93	93	93	95	70	82	89	89	61	33	5	5
MCV2	-	-	-	-	_	_	-	_	_	-	_	_	_	_	_
PCV3	-	-	-	-	-	-	-	_	-	-	-	-	-	-	_
Pol3	99	93	88	84	79	74	88	91	93	80	80	80	78	70	62
RCV1	93	92	92	93	93	93	95	70	82	89	89	61	33	5	_
RotaC	-	-	-	-	-	-	-	-	-	-	-	-	_	-	-

http://apps.who.int/immunization\_monitoring/globalsummary/; 2017-11-7



### Hepatitis B prevention-immunization

 Universal HepB immunization schedule: at birth, 1 mon and 6 mon of age by domestic monovalent vaccines



 Pre-license clinical study of Hexaxim (Sanofi-Pasteur) in Korea

Vaccine 35 (2017) 4022-4028

Contents lists available at ScienceDirect	n
	Vaccine
Vaccine	white
Vaccine	SYVE
ELSEVIER journal homepage: www.elsevier.com/locate/vaccine	

Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP~T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

CrossMark

Yun-Kyung Kim<sup>a</sup>, Emmanuel Vidor<sup>b</sup>, Hwang Min Kim<sup>c</sup>, Son Moon Shin<sup>d</sup>, Kyung-Yil Lee<sup>e</sup>, Sung-Ho Cha<sup>f</sup>, Sang Hyuk Ma<sup>g</sup>, Dong Ho Kim<sup>h</sup>, Jin Lee<sup>i</sup>, Su Eun Park<sup>j</sup>, Hyunju Lee<sup>k</sup>, Jong-Duk Kim<sup>l</sup>, Ki Hwan Kim<sup>m,1</sup>, Kyung-Hyo Kim<sup>n</sup>, Jong-Hyun Kim<sup>o,\*</sup>, A3L31 Study GroupYae-Jean Kim<sup>p</sup>, Dae Sun Jo<sup>q</sup>, Hyun Hee Kim<sup>r</sup>, Jin Han Kang<sup>s</sup>, Hee Soo Kim<sup>s</sup>, Joon Bang<sup>t</sup>, Yongho Oh<sup>u</sup>



Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

Hanoi, Vietnam, July 2018

Korea, Republic

### Hepatitis B prevention-immunization

HepB birth dose coverage HepB3 coverage 2500,000 2500,000 s 200,000 B d alu B b a 1500,000 1000,000 500,000 2000,000 HepB3 administered dose .80 80 08 40 Hep 500,000 2011 2001 2003 2009 2010 2012 2013 2000 2001 2002 2004 2005 2006 2008 2012 2015 2010 2011 000 201A 2002 2009 2010 2001 2000 100 →Administrative coverage →WUENIC Doses Administrative coverage — WUENIC Doses

http://apps.who.int/immunization\_monitoring/globalsummary/countries?countrycriteria%5Bcountry%5D%5B%5D=KOR#; 2018-7-19



Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination

Hanoi, Vietnam, July 2018

Korea, Republic

### Perinatal hepatitis B prevention

 In July 2000, The National Health Insurance cover the costs related to all the antenatal tests including HBsAg testing

HBsAg testing status in >100 maternity hospitals (2003)

Test	Hospital	s doing tests for pregn	ant women
	<b>All</b> (% )	High risk only (% )	None (%)
HBsAg	99.7	0.3	0.0
Anti-HBs	93.5	1.5	2.1

Seo K, et al. Evaluation of antenatal hepatitis B screening and neonatal immunization program of Korean hospitals. KCDC, 2003

- Recommended schedule of HepB perinatal prophylaxis in Korea
  - within 12 hours of birth HBIG 0.5 mL (100-125 IU) + 1<sup>st</sup> HepB vaccine
  - 1 month of age
    2<sup>nd</sup> HepB vaccine
  - 6 months of age 3<sup>rd</sup> HepB vaccine
  - 9-15 months of age Serologic test for HBsAg, anti-HBs



## Hepatitis B Perinatal Transmission Prevention Program in Korea

- Launched in July 2002
- In conjunction with the Korean Medical Association
- Government covers the 100% cost of
  - HBIG
  - Three doses of hepatitis B vaccine
  - HBsAg and anti-HBs testing
  - $\checkmark$  For all infants born to HBsAg positive mothers

#### Program outcome [2002-2010]

	Outcome	Viral markers	Numbers	Rates (%)
:	Success	HBsAg (-) /anti-HBs (+)	64,650	92.36
		HBsAg (-) /anti-HBs (-)	3,151	4.50
	Fail	HBsAg (+) /anti-HBs (-)	2,153	3.08
		HBsAg (+) /anti-HBs (+)	45	0.06
		Total	69,999	100.0

- Registered rate of program (2010): 98.1%

- Total registered cases = 125,855

- Tested cases for HepB viral markers = 69,999 (55.6%)
- ✓ Outcome: succeeded 96.86%, failed 3.14%

(HBeAg+ rate of child bearing women≒36%)

Kim JH , et al. The appraisement of perinatal hepatitis B virus transmission control program in the Republic of Korea. KCDC, 2011



### WPRO Hepatitis B control certification [2008] Korea, Republic

Report of Certification Panel for achievement of hepatitis B control goal in South Republic of Korea

The Republic of Korea submitted their request for certification of achievement of the hepatitis B control goal on April 4, 2008. The certification panel reviewed the original documents and subsequent response to the queries raised by members of the panel. Based on this review, the certification panel reached the unanimous conclusion that HBsAg scroprevalence is less than 1% among children born after 1992 and who are at least 5 years old. Hence, the Republic of Korea has effectively achieved the final regional goal of <1% chronic HBV infection rates among children at least five years of age.

The key evidence informing this conclusion were:

- The nationwide representative sero-survey among the population 10 years of age or older conducted as part of the 3<sup>rd</sup> Korca National Health and Nutrition Examination Survey, 2005: This survey showed that while the overall HBsAg positive rate among the population 10 years or older is 3.7% (3.2-4.2)
   [4.4% among men and 3% among women], the seroprevalence was 0.2% [0.0-0.6%] among the population 10-14 years old. This latter group was born between 1991-1994 after the start of nationwide hepatitis B immunization.
- 2) The special hepatitis B scro-survey of the 4-6 year old population (2007): This was a nationwide representative survey sampling 12 children aged 4-6 years of age from each of the 251 public health centers distributed across the country (one center for each of 251 cities/counties) which provides free basic preventive and outpatient chinical services. A total of 3012 children were sampled with only 10 children refusing to participate. This survey noted a seroprevalence of 0.2% (0.0-0.3%). This survey also noted a vaccination coverage rate of 99.7% (99.5% 99.9%) with three doses of hepatitis B vaccine among children whose vaccination records could be retrieved<sup>1</sup>.

Although these surveys were not population based, we are all convinced that they are representative of the Korean population.

The results from these two serosurveys support the conclusion that South Korea has achieved the final regional goal for less than 1% chronic HBV infection among children at least five years old.

# First country verified for hepatitis B control in WPRO

- HepB vaccination coverage rate = 94.5%
- Sero-prevalence of HBsAg
  0.2% in 10~14 yrs of age
  0.2% in 4~6 yrs of age



Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination